Reach Out and Read serves 4.8 million children, but 23% of parents at 3 centers reported clinician modeling, tied to the greatest home literacy gains.
|Videos|April 12, 2021
Debunking 4 Myths Around Mass Shootings
Author(s)Tony Thrasher, DO, MBA, CPE, DFAPA
As the recent waves of violence show, a conversation needs to be had on mass shootings and gun violence...
Advertisement
Tony Thrasher, DO, DFAPA, talks about 4 crucial misunderstandings about mass shootings.
Dr Thrasher is the president of the American Association for Emergency Psychiatry (AAEP) and the medical director of crisis services in Milwaukee county, Wisconsin.
Advertisement
Related to this article
New data shows cannabis dominates teens’ substance-related ER visits, often with alcohol or stimulants, urging better screening and intervention for psychosis, vomiting.
How can you address envy in your creative patients?
Compass Pathways has completed its submission of an NDA to the FDA for COMP360 psilocybin for treatment-resistant depression.
Lisa Harding, MD, says ECT, ketamine, TMS, and VNS can work, but evidence on what comes after acute response remains thin.
Why D2 blockade alone falls short in schizophrenia, and what neurotransmitter, genetic and neuroimaging research means for treatment-resistant patients.
Discover expanded psychiatry coverage with new podcasts, interactive digital issues, and event reporting—we are your always-on media hub delivering fresh insights year-round.
GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
Advertisement
Advertisement
Trending on Psychiatric Times
1
NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant Depression
2
Shared Decision-Making in MDD Treatment Across the Lifespan
3
Schizophrenia: A Telltale of the Brain’s Complexity
4
Death, Taxes, and Envy: Treating Creative Patients
5